NCT00022659 · OUTCOME
Number of Participants and Degree of Toxicity of Bevacizumab in This Cohort of Patients as Assessed by CTC.
Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer · Source last updated 2019-07-24
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Assessed every cycle while on treatment, 30 days after the last cycle of treatment, up to 5 years.
Analysis population: Eligible and evaluable patients
Groups in this outcome
Grade 1 (CTCAE v 2.0)
Number of patients who experienced a grade 1 event using Common Toxicity Criteria version 2.0
Grade 2 (CTCAE v 2.0)
Number of patients who experienced a grade 2 event using Common Toxicity Criteria version 2.0
Grade 3 (CTCAE v 2.0)
Number of patients who experienced a grade 3 event using Common Toxicity Criteria version 2.0
Grade 4 (CTCAE v 2.0)
Number of patients who experienced a grade 4 event using Common Toxicity Criteria version 2.0
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Grade 1 (CTCAE v 2.0) | 62 |
|---|
| Grade 2 (CTCAE v 2.0) | 62 |
|---|
| Grade 3 (CTCAE v 2.0) | 62 |
|---|
| Grade 4 (CTCAE v 2.0) | 62 |
|---|
Reported measurements
Leukopenia
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 18 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Thrombocytopenia
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Neutropenia
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Anemia
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 18 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Hematologic
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Allergy
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Hearing
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Cardiovascular
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 12 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 7 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Coagulation
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 9 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Constitutional
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 22 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Dermatologic
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 10 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Endocrine
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Gastrointestinal
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 26 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Genitourinary/Renal
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 5 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 14 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Hemorrhage
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 14 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Hepatic
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 19 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Infection
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Lymphatics
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Musculoskeletal
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Metabolic
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 17 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Neurologic
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 16 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Ocular
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Pain
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 26 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Pulmonary
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Sexual/Reproductive
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Grade 1 (CTCAE v 2.0) | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 2 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 3 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Grade 4 (CTCAE v 2.0) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 18
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- title
- Leukopenia
- categories
- measurements
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- title
- Thrombocytopenia
- categories
- measurements
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- title
- Neutropenia
- categories
- measurements
- group Id
- OG000
- value
- 18
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- title
- Anemia
- categories
- measurements
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 0
- title
- Hematologic
- categories
- measurements
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 0
- title
- Allergy
- categories
- measurements
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- title
- Hearing
- categories
- measurements
- group Id
- OG000
- value
- 12
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 7
- group Id
- OG003
- value
- 1
- title
- Cardiovascular
- categories
- measurements
- group Id
- OG000
- value
- 9
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 0
- title
- Coagulation
- categories
- measurements
- group Id
- OG000
- value
- 22
- group Id
- OG001
- value
- 6
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 0
- title
- Constitutional
- categories
- measurements
- group Id
- OG000
- value
- 10
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- title
- Dermatologic
- categories
- measurements
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- title
- Endocrine
- denoms
- counts
- group Id
- OG000
- value
- 62
- group Id
- OG001
- value
- 62
- group Id
- OG002
- value
- 62
- group Id
- OG003
- value
- 62
- units
- Participants
- groups
- description
- Number of patients who experienced a grade 1 event using Common Toxicity Criteria version 2.0
- id
- OG000
- title
- Grade 1 (CTCAE v 2.0)
- description
- Number of patients who experienced a grade 2 event using Common Toxicity Criteria version 2.0
- id
- OG001
- title
- Grade 2 (CTCAE v 2.0)
- description
- Number of patients who experienced a grade 3 event using Common Toxicity Criteria version 2.0
- id
- OG002
- title
- Grade 3 (CTCAE v 2.0)
- description
- Number of patients who experienced a grade 4 event using Common Toxicity Criteria version 2.0
- id
- OG003
- title
- Grade 4 (CTCAE v 2.0)
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Eligible and evaluable patients
- reporting Status
- POSTED
- time Frame
- Assessed every cycle while on treatment, 30 days after the last cycle of treatment, up to 5 years.
- title
- Number of Participants and Degree of Toxicity of Bevacizumab in This Cohort of Patients as Assessed by CTC.
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle